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Abstract
Purpose To assess how vitreomacular adhesion (VMA),
vitreomacular traction (VMT), and macular holes (MH)
evolve, and to assess visual acuity outcomes associated with
different management strategies for each subgroup.
Methods Retrospective, single-center, observational study of
400 patients (556 eyes) who presented with optical coherence
tomography (OCT) findings related to tractional diseases of
the vitreomacular interface (187 with bilateral disease). The
outcomes measured include prevalence of symptoms, rates of
disease stabilization, spontaneous resolution, and disease pro-
gression necessitating surgical intervention. Size of VMA/
VMTwas not measured.
Results Vision loss and metamorphopsia were the leading
causes for referral. Patients were followed for a mean of
10.9 months (median 6.9 months). Spontaneous resolution
occurred in 22.7 % (46/203) of eyes with VMT and in 7.3 %
(9/124) of eyes with VMA (P< .001). In the former group,
34.1 % (14 eyes) showed improved visual acuity (P= .001).
During follow-up, 11.3 % (14/124) of eyes with VMA
showed disease progression; six (4.8 %) developed a macular
hole. Eleven of the 203 eyes with VMT (5.4 %) developed a
macular hole; 52 of 203 eyes with VMT (25.6 %) had disease
progression that resulted in patients opting for pars plana vit-
rectomy (PPV). Of the eyes with VMA, 4.8 % (6/124) had
disease progression resulting in patients opting for PPV.
Conclusions Better visual acuity outcomes were found in
eyes with spontaneous resolution compared to the other
groups. Spontaneous resolution of VMT and VMAwas rare,
whereas disease progression resulting in PPV was more
common.
Keywords Retina .Macula .Macular hole . Vitreomacular
adhesion . Vitreomacular interface . Vitreomacular traction
Introduction
Posterior vitreous detachment (PVD) is a consequence
of aging whereby the vitreous liquefies and detaches
from the internal limiting lamina of the retina [1, 2].
When the liquefaction exceeds vitreoretinal dehiscence
and traction is exerted at the vitreomacular interface
(VMI), an anomalous PVD occurs [1].
Numerous potential anatomic consequences of anom-
alous PVD exist. Forced tractional separation (either
surgical or mechanical) between the posterior vitreous
and the internal limiting membrane (ILM) has shown
pockets of extreme adhesion; subsequent methods to
break the bond can result in retinal tears and dialyses
[2] . Othe r po ten t i a l ana tomic e ffec t s inc lude
vitreomacular adhesion (VMA) and vitreomacular trac-
tion (VMT) syndromes or hemorrhage in the presence
of concomitant disease [1]. Focal VMT can result in
macular hole (MH) formation or tractional cystoid mac-
ular edema, while broad VMT has been associated with
epiretinal membrane (ERM) and diffuse retinal thicken-
ing, among others [3]. However, the progression of
VMA and VMT is not consistent among all patients,
and data on the natural history are limited.
Visual acuity (VA) is usually preserved in early VMT, but
is progressively impacted as a macular hole develops [4].
VMT can also lead to visual disturbances, among them
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metamorphopsia, photopsia, and micropsia [5–11]. There are
very limited data on the impact of these symptoms on visual
quality in patients with VMT; however, metamorphopsia has
been associated with decreased vision-related quality of life in
other vitreoretinal disorders [5, 6, 12–15], and it has been
suggested that it may be more important to overall perception
of visual function than visual acuity [13].
In patients with tractional VMI disease, Bwatchful waiting^
has been the traditional standard of care. Pars plana vitrectomy
(PPV) is typically reserved for more severe or progressive
cases [6, 16]. In some patients, watchful waiting results in
favorable outcomes, including spontaneous resolution of
VMA [10]. However, anatomic improvements do not neces-
sarily correlate with visual function (VA or symptoms) [10],
and PPV has been reported to have a relatively modest impact
on VA [17].
Epidemiological data on VMA, VMT, and MH also are
limited [18–22]. In today’s real-world clinical settings, a con-
firmed diagnosis on spectral-domain OCT (SD-OCT) has
made it much easier for clinicians to examine the vitreoretinal
interface and identify tractional diseases, often before visual
loss becomes irreversible [10, 11, 23, 24]. However, since the
incorporation of SD-OCT, few large-scale studies have been
published.
The goal of this retrospective analysis of electronic
medical records was to both extract data on VMA,
VMT, and MH from a clinical setting, and to assess
how the condition in each subgroup evolves. We
planned to determine patient characteristics at baseline,
the prevalence of symptoms, and the clinical course of
the disease in the prepharmacologic vitreolysis era, in-
cluding the incidence of spontaneous resolution, PPV,
and disease progression, as well as the impact of treat-
ment practices on VA outcomes. Our analysis represents
the largest observational cohort to date that includes
patient follow-up and with a confirmed diagnosis of
tractional disease of VMI using SD-OCT imaging [10,
22, 25–36].
Methods
This was a retrospective, single-center, observational study
conducted with patients attending in the ophthalmology unit
of the University Hospitals Leuven (Universitaire
ziekenhuizen Leuven [UZLeuven]), a large tertiary care center
in Flanders, Belgium. The time frame for this study
encompassed the period before a pharmacologic treatment
for VMT was commercially available. At that time, the stan-
dard of care at our center was to recommend PPV for patients
presenting with a macular hole. Patients with VMA or VMT
were predominantly managed by watchful waiting until
disease progression reached a threshold where the patient
opted for surgical intervention.
Inclusion criteria
Consecutive patients presenting at the center between July
2009 and August 2013 were included if they had SD-OCT
findings related to tractional diseases of the VMI (as recently
classified by Duker et al.) [37]. Both symptomatic and asymp-
tomatic patients were included. For patient allocation, our
hospital has developed subcodes to the ICD coding system
specifically for MH and VMA. These subcodes were used to
locate all patients in the database since 2009 that had these
specific ocular conditions, and this information was used to
develop the consort diagram represented in Fig. 1.
Exclusion criteria
Patients were excluded from the study if there was concomi-
tant retinal pathology potentially influencing VA during
follow-up (ie, proliferative diabetic retinopathy, history of
panretinal photocoagulation, or recurrent retinal detachment),
had isolated ERM without VMA or VMT (ie, isolated pucker
formation), or if they participated in clinical trials using
ocriplasmin. Broad attachments were not excluded. VMTwith
concomitant ERM was defined as two separate layers that
could be distinguished on OCT, one being the posterior hya-
loid membrane and one being the epiretinal membrane.
Technique
All surgeries were 23-gauge transconjunctival vitrectomies,
with internal limiting membrane (ILM) peel performed in all
cases after staining with ILM-Blue (DORC, Netherlands).
With respect to lens status, the recommended treatment algo-
rithm of a combined phaco-vitrectomy was performed for all
consenting phakic patients over 50 years of age. In these
cases, lens surgery was performed first, followed by vitrecto-
my. All surgeries for macular hole involved the use of silicone
oil, where a second surgery was performed 3 months after the
first surgery to remove the oil. Silicone oil was used due to its
increased density (heavier than water), providing a good
tamponade of both the inferior and posterior pole in normal
head posturing, obviating the need for postoperative face-
down positioning [38–40].
Data collection and analysis
Raw clinical and OCT data (Cirrus OCT, Carl Zeiss Meditec,
Jena, Germany) were extracted from the electronic medical
records system used in the tertiary care center (Klinisch
WerkStation [Clinical Workstation], developed at
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UZLeuven, Belgium). Data analysis was performed by an
independent statistician.
VA was collected in decimal format and converted to
logMAR for statistical analysis. A VA change of ≥0.2
logMAR units (corresponding to two ETDRS lines) was
deemed to be clinically meaningful.
For SD-OCT, a 5-series 6-mm line scan was performed
over the macular area, as well as a 512×128 macular cube
scan. SD-OCTs were examined from both eyes. All eyes with
tractional pathology of the VMI were included and classified
according to the recently published International
Vitreomacular Traction Study Group (IVTS) classification in
four groups with increasing disease stage: VMA, VMT, MH
with VMT, and MH without VMT [37]. Size of VMA/VMT
was not measured. In cases of bilateral involvement, the eye
with worse pathology was considered to be the index eye. If
both eyes had the same disease stage, the eye with worst visual
acuity was considered to be the index eye.
Collected baseline data included age, gender, and duration
of symptoms prior to baseline visit, source, and reason for
referral, VA, presence of metamorphopsia, concomitant
ERM, and history of diabetes. The outcomes of interest were
evolution of visual acuity, incidence of PPV, spontaneous res-
olution of traction, and progression of disease. Clinically
meaningful changes in visual acuity were defined as changes
equivalent to two or more ETDRS lines. Visual acuity
measurements less than 30 days after PPV were excluded
from analyses. Kaplan-Meier analysis was used for cumula-
tive incidence curves representing time to PPVand spontane-
ous resolution. Nonparametric tests were used for compari-
sons of vitreomacular disease groups. The Wilcoxon
matched-pairs signed-ranks test was used to evaluate the evo-
lution of VA over time. VA outcomes in VMT patients were
compared across outcomes (PPV, spontaneous resolution,
continued watchful waiting).
A logistic regression model was fit with potential baseline
predictors for vitrectomy in VMT eyes only. Age, gender,
metamorphopsia, VA, and duration of symptoms prior to di-
agnosis were included. Nonsignificant (P≥ .05) baseline vari-
ables were stepwise dropped from the model until all remain-
ing predictors were significant. Statistical analysis was per-
formed using Stata version 13.1 for Mac (StataCorp LP, TX,
USA).
The study protocol and investigators for the site were ap-
proved by the ethics committee of the UZLeuven.
Results
In total, 496 patients with 681 affected eyes were included for
baseline analysis. Of those, 400 patients (556 eyes) had at least
one follow-up visit (See Fig. 1 for patient disposition). There
Fig. 1 Patient disposition flow diagram (CONSORT). Flow diagram depicting the progress and disposition of patients, from identification in the
database through analysis and inclusion/exclusion into dataset
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were no differences in demographic characteristics or distri-
bution of tractional vitreomacular disease between those with
or without follow-up. Women made up two-thirds of the co-
hort. Following the classification of the International
Vitreomacular Traction Study Group [37], at baseline, the ma-
jority of eyes were diagnosed with VMT (37.0 %), followed
byMHwithout VMT (31.3 %), VMA (22 %), and finally MH
with VMT (9.7 %). In patients with follow-up data, the distri-
bution among groups was similar: VMT (36.5 %), MH with-
out VMT (31.7 %), VMA (22.3 %), and MH with VMT
(31.7 %) (Table 1). Therefore, the distribution of patients with
at least one follow-up visit was representative of the whole
patient population. These patients were followed for a mean of
10.9 months (median 6.9 months).
Disease characteristics
A total of 496 patients had a bilateral evaluation at initial
presentation, of which 185 patients (37.3 %) had bilateral
tractional VMI disease (Table 2).
The proportion of eyes with metamorphopsia at baseline
was highest in eyes with MH with or without VMT (92.4 %
and 83.1 %, respectively), followed by those with VMT
(52 %). However, even in the VMA group, 27/150 (18.0 %)
had symptoms of metamorphopsia, despite a lack of tractional
abnormalities on OCT (Fig. 2). The boxplot in Fig. 3 shows
how baseline VA progressively worsened with advancing
stage of VMI disease (nonparametric test for trend: P< .001).
Patient outcomes
Table 3 describes the overall patient outcomes; almost half the
patients underwent PPV.
Disease progression During follow-up, 11.3 % (14/124) of
eyes with VMA showed disease progression, with six eyes
(4.8 %) developing a macular hole. Of the 203 eyes with
VMT, 11 (5.4 %) developed a macular hole; five of these
(45.5 %) were within the first month. Within the BMH with
VMT^ group, 15.1 % (8/53) of eyes evolved toward detach-
ment; none of the macular holes closed spontaneously
(Fig. 4).
Spontaneous resolution Eyes with VMTwere more likely to
experience spontaneous resolution of traction than eyes with
VMA (Fig. 5): 22.7 % (46/203) of eyes vs. 7.3 % (9/124) of
eyes, respectively, within 1 year after diagnosis (Fisher’s exact
test; P< .001).
Vitrectomy In the BMHwith VMT^ group, 88.7 % (47/53) of
eyes underwent PPV, similar to the 86.4 % (152/176) of eyes
in the BMH without VMT^ group. Although most eyes with
VMTwere managed by watchful waiting, 25.6 % (52/203) of
VMT eyes underwent PPV during follow-up, mostly because
their diseased worsened. Even in the VMA group, 4.8 %
(6/124) of eyes underwent vitrectomy, four because of
disease-stage progression (Fig. 6).
Visual acuity outcomesTable 4 shows the change in VA from
baseline to last observation. Visual acuity outcomes differed
depending on the stage of VMI disease.More than 50% of the
220 eyes with a macular hole at baseline had an improved VA
at their last visual assessment. In eyes with a macular hole that
underwent PPV, 57.9 % (110/190) had VA improvement,
while VA in the 30 eyes with a macular hole that did not
undergo PPV remained stable (18 eyes, 60.0 %) or worsened
(six eyes, 20 %; Fisher’s exact test, P< .001). Nevertheless,
13.2 % (13/190) of eyes with a macular hole that underwent
PPVexperienced worsening VA. In eyes affected by VMA or
VMT, VA remained largely stable during follow-up.
VA outcomes in eyes with VMT There were 46 eyes with
spontaneous resolution in the VMT group (Fig. 7). The ma-
jority of these eyes (69.6 %, 32/46) resolved within 180 days.
VA data were available for 41 of these eyes (89 %). A total of
14 eyes (34.2 %) had improved VA at the last observation
(Fig. 8, middle panel; P= .001). The majority of eyes in the
VMT group (105/188) were followed under continued obser-
vation, ie, they were not actively treated and did not experi-
ence spontaneous resolution. Of these 105 eyes under contin-
ued observation, 9.5 % did have improved VA and 7.6 % had
decreased VA (Fig. 8, right panel). The median change in VA
was not statistically significant (P= .97).
In the subgroup of 52 VMT eyes that underwent PPV, VA
data were available for 42 eyes (81 %), of which 35.7 % had
improved VA and 14.3 % had decreased VA compared to
baseline. Although there was a trend to improved VA at the
end of the observation period, this was not significant (Fig. 8,
left panel; P= .09). Overall, of the 188 eyes with VMT, only
39 (20.7 %) had improved VA at the last observation, whereas
16 (8.5 %) worsened.
Complications No retinal detachments were reported after
surgery. No phototoxic effects were observed; note that
ILM-Blue does not have phototoxic properties such as those
described after using indocyanine green (ICG) for staining the
ILM. No late reopenings of macular holes were reported.
Since all phakic eyes had lens surgery during the first inter-
vention (all patients were >50 years of age and consented to
surgery), no cataract development was reported.
Independent predictors of PPV in eyes with VMT
Metamorphopsia increased the odds of patients electing to
undergo PPV by a factor of 3.33. Being female increased the
odds of undergoing vitrectomy by a factor 2.45 compared to
being male. For a difference of 1 ETDRS line of baseline VA,
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the odds of undergoing PPV decreased by 13 % (odds ratio
0.87) (Table 5).
Discussion
In this retrospective analysis, the burden of tractional VMI
disease was found to increase with each progressive stage of
the disease (VMA<VMT<MH with VMT<MH without
VMT). The presence of metamorphopsia, considered a hall-
mark symptom of vitreomacular pathology [6–9, 12, 14, 15],
correlated with the worsening disease stages. Similarly, wors-
ening VMI disease was associated with increased vision loss.
We found metamorphopsia to be a frequent cause for referral
to our center. Although metamorphopsia alone was not the
indication for vitrectomy, it was one of the key symptoms
bringing patients to the clinic, and therefore, was one of the
factors considered when choosing PPV. Indeed, the National
Institute for Health and Care Excellence (NICE) in the UK has
officially stated that having metamorphopsia has the same
burden on the quality of life as a 2-line decrease in VA. In
our analysis, having metamorphopsia was a strong indepen-
dent predictor of vitrectomy in eyes with VMT, tripling the
odds of a patient opting to undergo PPV. This finding suggests
that VA measurement only may not be the most adequate
correlate of disease severity.
Our findings underscore that watchful waiting may not be
an appropriate course of action, as delayed treatment can lead
to further disease progression. In eyes with VMA, 1 in 10 had
disease progression and 1 in 20 progressed to a threshold











Age, years, mean (SD) 68.9 (9.22) 72.6 (8.99) 68.7 (6.49) 68.7 (10.05) 70.2 (9.35)
Male: n (%) 38 (30.7) 82 (40.4) 10 (18.9) 57 (32.4) 187 (33.6)























Vision loss (far), n (%) 15 (50.0) 100 (54.6) 25 (48.1) 99 (60.7) 239 (55.8)
Vision loss (near), n (%) 14 (46.7) 63 (34.4) 17 (32.7) 49 (30.1) 143 (33.4)
Any vision loss, n (%) 17 (56.7) 112 (61.2) 32 (61.5) 104 (63.8) 265 (61.9)
Metamorphopsia, n (%) 7 (23.3) 45 (24.6) 29 (55.8) 67 (41.1) 148 (34.6)
Baseline characteristics:
logMAR, mean (SD) 0.11 (0.196) 0.35 (0.310) 0.72 (0.348) 0.86 (0.330) 0.49 (0.422)
Metamorphopsia: n (%) 22 (17.7) 102 (50.3) 49 (92.5) 146 (83.0) 319 (57.4)
ERM, n (%) 4 (3.2) 28 (13.8) 0 (0.0) 1 (0.6) 33 (5.9)
Diabetes, n (%) 10 (8.1) 26 (12.8) 2 (3.8) 27 (15.3) 65 (11.7)
ERM, epiretinal membrane; logMAR, logarithm of the minimum angle of resolution; MH+VMT, macular hole with vitreomacular traction; MH-VMT,
macular hole without vitreomacular traction; SD, standard deviation; VMA, vitreomacular adhesion; VMT, vitreomacular traction.
Table 2 Fellow eye disease
status in relation to index eye
disease status
Index eye vitreomacular disease stage
Fellow eye vitreomacular
disease status
VMA VMT MH+VMT MH-VMT Total
No vitreomacular disease 25 (69.4) 116 (61.1) 33 (54.1) 137 (65.6) 311 (62.7)
VMA 11 (30.6) 35 (18.4) 15 (24.6) 53 (25.4) 114 (23.0)
VMT 39 (20.5) 11 (18.0) 12 (5.7) 62 (12.5)
MH+VMT 2 (3.3) 3 (1.4) 5 (1.0)
MH-VMT 4 (1.9) 4 (0.8)
Total 36 (100.0) 190 (100.0) 61 (100.0) 209 (100.0) 496 (100.0)
ERM, epiretinal membrane;MH+VMT; macular hole with vitreomacular traction;MH-VMT, macular hole with-
out vitreomacular traction; SD, standard deviation; VMA, vitreomacular adhesion; VMT, vitreomacular traction.
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where the patient opted for PPV. A total of 5 % of eyes with
VMT developed a new macular hole, almost half in the first
month after diagnosis, and the majority of those new macular
holes progressed to a threshold where the patient opted for
PPV. Moreover, none of the MH with VMT cases showed a
spontaneous closure, even if 15.1 % showed a spontaneous
Fig. 2 Metamorphopsia at baseline by stage of VMI disease (N= 681).
Graph representing the proportion of patients at baseline with
metamorphosia at different stages of vitreomacular disease (VMA,
VMT, MH+VMT, MH-VMT). CI, confidence interval; MH +VMT,
macular hole with vitreomacular traction; MH-VMT, macular hole
without vitreomacular traction; VMA, vitreomacular adhesion; VMI,
vitreomacular interface; VMT, vitreomacular traction
Fig. 3 Baseline visual acuity by
stage of VMI disease. Boxplot
depicting baseline visual acuity
for patients with different stages
of tractional VMI disease.
logMAR, logarithm of the
minimum angle of resolution;
MH+VMT, macular hole with
vitreomacular traction; MH-
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VMT release, rendering them unsuitable for treatment with
pharmacological vitreolysis that could potentially induce a
nonsurgical closure (previously shown in 40 % of MH with
VMT [41, 42]). In the VMT patients, only the subgroup show-
ing spontaneous resolution of traction demonstrated an in-
creased VA outcome compared to baseline, whereas this was
not the case in the group without VMT release, nor in the
group that underwent PPV (where preoperative VAwas usu-
ally decreased to a level far lower compared to the baseline
measurement).
Eyes with a macular hole at presentation (with or without
VMT) were recommended for PPV. In our analysis, 199 of
229 eyes with a macular hole underwent PPV (86.9 %), the
vast majority within the first 3 months. Thirty patients
(13.1 %) with macular holes declined surgery. Only one eye
(in a young patient with a post-traumatic macular hole) had a
spontaneous closure.
Intraoperative PPV complications are not uncommon, with
cataract formation likely in phakic patients [16], which is often
a reason to opt for watchful waiting rather than rush patients
with milder forms of VMI into PPV.
In this study, a high percentage of patients underwent
PPV—more than 85 % in each of the MH groups and more
than 25 % in the VMT group. The reported vitrectomy rates
could have been even higher since the center was aware of
pharmacologic vitreolysis and was enrolling patients in the
Safety and Efficacy Study of Microplasmin in for Non-
Surgical Treatment of Focal Vitreomacular Adhesion (MIVI-
Table 3 Outcomes in eyes with












Baseline visual acuity: N 124 198 53 176 551






Mean Snellen 20/25 20/45 20/105 20/145 20/61
Last observed visual acuity: N 124 193 49 171 537








Mean Snellen 20/28 20/42 20/73 20/94 20/51
Spontaneous resolution, n (%) 9 (7.3) 46 (22.7) N/A N/A n/a
Vitrectomy, n (%) 6 (4.8) 52 (25.6) 47 (88.7) 152 (86.4) 257 (46.2)
Progression, n (%) 14 (11.3) 11 (5.4) 8 (15.1) N/A N/A
Progression to MH, n (%) 6 (4.8) 11 (5.4) N/A N/A N/A
logMAR, logarithm of the minimum angle of resolution; MH+VMT, macular hole with vitreomacular traction;
MH-VMT, macular hole without vitreomacular traction; N/A, not applicable; SD, standard deviation; VMA,
vitreomacular adhesion; VMT, vitreomacular traction
Fig. 4 Flow chart on patient
outcomes by baseline disease.
Flow diagram depicting
proportion of patients progressing
through different stages of VMI
disease and treatment. Patients
were followed for a mean of
10.9 months (median
6.9 months). MH+VMT,
macular hole with vitreomacular
traction; MH-VMT, macular hole
without vitreomacular traction;
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8) study, thereby disqualifying them from inclusion in this
analysis.
Others have reported much higher percentages of spontane-
ous resolution (ranging from 11% to 53%), but these series also
had far fewer patients [10, 22, 25–30, 34–36]. Larsson et al. [26]
reported on 11 patients (11 eyes) with VMT who had deferred
PPV for 3months, and during that time, no cases of spontaneous
resolution were observed. Odrobina et al. [27] suggested vitre-
ous surface adhesion and ERMwere closely tied to spontaneous
resolution, and that a higher spontaneous resolution of VMT
may have been the result of fewer ERMs. In our analysis of eyes
with VMT, 22.7 % experienced spontaneous resolution, but
5.4 % progressed to a macular hole and for another 25.6 %
patients opted for PPV (almost half of them within the first
month of diagnosis). One reason patients may opt for PPV is
that studies have shown that spontaneous resolution may take a
long time to occur (mean follow-ups exceeded 2 years in some
studies) and that symptoms may persist or worsen over time
even after successful resolution [22, 43].
Our observations further add to the literature on VMT.
Although a large proportion of eyes in the VMT group had
Snellen VA of 20/40 at time of diagnosis, 55.2 % had been
referred for vision loss and 22.2 % for metamorphopsia.
Those who underwent PPV registered only a median
logMAR change of −0.10, underscoring that VA alone may
underestimate disease severity. Of interest, however, is that
14.3% of eyes with VMT that underwent PPV had a clinically
meaningful loss of VA. Of those in the BMH with VMT^
group, 92.5 % were diagnosed with metamorphopsia and
54.7 % had been referred for metamorphopsia even though
baseline VAwas 20/80.
Almost 40 % of all patients had bilateral involvement,
which was higher in this group of patients than anticipated.
As might be expected, bilateral disease results in substantially
more compromised vision than unilateral cases. As this is a
progressive disorder with limited success in spontaneous res-
olution, we recommend continued vigilant follow-up in an
affected fellow eye.
Our cohort was followed for a mean of 10.9 months (me-
dian 6.9 months). Other studies had longer follow-up times,
but observed fewer numbers of patients. For instance, Hikichi
et al. [22] followed patients for 60 months with a study of
N=53 eyes. Similarly, Dimopoulos et al. [30] had a median
follow-up of 594 days (19.5) months with a cohort of N=46
patients, and Theodossiadis et al. [34] followed 192 cases with
a follow-up of 21.8 ± 10.6 months. Other study follow-up
times ranged from none to 15.8±8.4 months [10, 25–29, 31,
32, 35, 36].
Fig. 5 Time to resolution in eyes with VMT or VMA. Kaplan Meyer graph showing the proportion of patients with VMT or VMA at baseline that
achieved spontaneous resolution within 1 year of diagnosis. VMA, vitreomacular adhesion; VMT, vitreomacular traction
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This study has several strengths, including that it is the
largest cohort of patients and eyes with VMI. Other observa-
tional cohorts ranged in size from 11 to 214 [10, 22, 25–36].
Our analysis also included the largest number of subgroups
and used the most up-to-date disease classifications, from the
International Vitreomacular Traction Study Group [37].
Furthermore, in addition to using the most technologically
advanced diagnostics available at the time (SD-OCT) to con-
firm the diagnosis, the same SD-OCT device was used in all
patients during all follow-up visits. The ability of SD-OCT to
identify the various stages of VMI at earlier points in time has
been previously established [10].
However, this study is not without limitations. As a retro-
spective study, certain variables such as uniform follow-up
visits were not possible to establish. In addition, certain data
were not available that would have added to the analysis, such
as adhesion size and resolution of metamorphopsia. Patients
were enrolled from a single-center tertiary care center, which
may have a higher proportion of people with VMI referred for
diagnosis and may not be representative of other tertiary care
populations. As we noted, the number of PPVs in earlier
stages of the disorder may have been subject to inves-
tigator bias, as investigators were not proactively
counseling patients to undergo PPV, except in patients
Fig. 6 Time to PPV byVMI disease stage. KaplanMeyer graph showing
the proportion of patients with VMA, VMT, MH+VMT, and MH-VMT
who had PPV within 1 year of diagnosis. MH+VMT, macular hole with
vitreomacular traction; MH-VMT, macular hole without vitreomacular
traction; VMA, vitreomacular adhesion; VMT, vitreomacular traction;
VMI, vitreomacular interface
Table 4 Clinically meaningful
change in visual acuity by stage of
VMI disease
≥ 0.2 logMAR change VMA VMT MH+VMT MH-VMT Total
Worse: n (%) 9 (7.3) 16 (8.5) 9 (18.4) 22 (12.9) 56 (10.3)
Unchanged, n (%) 110 (88.7) 133 (70.7) 14 (28.6) 59 ( 4.5) 316 (9.4)
Improved: n (%) 5 (4.0) 39 (20.7) 26 (53.1) 90 (52.6) 160 (30.1)













logMAR, logarithm of the minimum angle of resolution; MH+VMT, macular hole with vitreomacular traction;
MH-VMT, macular hole without vitreomacular traction; Q1, interquartile 1; Q3, interquartile 3; VMA,
vitreomacular adhesion; VMI, vitreomacular interface; VMT, vitreomacular traction.
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with a macular hole, where PPV was performed expe-
ditiously. In addition, the lack of regularly scheduled
follow-up visits was also a limitation.
The present study (termed ReCoVit) was unable to address
which patients who present with VMA or VMT are likely to
spontaneously resolve and which will progress, nor does it
Fig. 7 Time to spontaneous resolution in eyes with VMT. Bar graph showing number of eyes in the VMT group with spontaneous resolution over time
(days). Each bar represents the number of resolutions per month. VMT, vitreomacular traction
Fig. 8 Evolution of visual acuity in patients with VMT. Scatter plot of
the evolution of visual acuity in VMT patients by outcome, illustrating
change in VA (improved, worsened, no change). Left panel: VMT eyes
without PPV or spontaneous resolution. Middle panel: VMT eyes with
spontaneous resolution. Right panel: VMT eyes undergoing PPV.
logMAR, logarithm of the minimum angle of resolution; PPV, pars
plana vitrectomy; VA, visual acuity; VMT, vitreomacular traction
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reveal any evidence of the occurrence of tractional diseases of
the VMI in a general population. Additional research is need-
ed to address this question, especially in today’s clinical set-
ting, given the regulatory and commercial availability of phar-
macologic vitreolysis that provides an alternative to watchful
waiting [42].
In conclusion, this retrospective analysis confirmed that
metamorphopsia is a hallmark symptom of vitreomacular pa-
thology, and that both vision loss and metamorphopsia in-
crease with disease stage severity. Our findings suggest there
is no clinical benefit in watchful waiting, and the delay in
treatment may result in poor visual outcomes even after res-
toration of the anatomical defect.
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